By inhibiting the lymphocyte activation gene 3 (LAG-3), the glucocorticoid-induced TNF receptor (GITR), and the T cell immune receptor with immunoglobulin and ITIM domain (TIGIT), the T cell antitumor response is improved, which leads to increased T cell effector and NK cell proliferation, resulting in a more efficient elimination of dormant tumor cells [2]. Here, LAG3 is linked to neoplasm.